Cited by 329Neuroscience and Neuropharmacology ResearchSchizophrenia research and treatmentTreatment of Major Depression

A Specific Role for NR2A-Containing NMDA Receptors in the Maintenance of Parvalbumin and GAD67 Immunoreactivity in Cultured Interneurons

Open access
Kinney, Jefferson W., Davis, Christopher N., Tabarean, Iustin, Conti, Bruno, Bartfai, Tamas, Behrens, M. Margarita·2006·The Journal of Neuroscience

Abstract

Several lines of evidence suggest that a hypoglutamatergic condition may induce a phenotypic loss of cortical parvalbumin (PV)-positive GABAergic interneurons, such as that observed in brain tissue of schizophrenic subjects. However, it is not known whether the loss of PV interneurons is a consequence of the hypoglutamatergic condition or a secondary aspect of the disease. We characterized the signaling and subunit expression of NMDA receptors in cultured cortical PV interneurons and determined whether a hypoglutamatergic condition, created by direct application of sublethal concentrations of ketamine or subunit-selective NMDA receptor antagonists, can affect the expression of the GABAergic markers as observed in vivo. Real-time PCR performed on mRNA isolated from single neurons showed that PV interneurons present a fivefold higher NR2A/NR2B ratio than pyramidal neurons. Brief, nontoxic, exposure to NMDA led to an increase in ERK1/2 (extracellular signal-regulated kinase 1/2) and cAMP response element-binding protein phosphorylation in PV interneurons, and this increase was blocked by the NR2A-selective antagonist NVP-AAM077. Application of the nonselective NMDA receptor antagonist ketamine, at sublethal concentrations, induced a time and dose-dependent decrease in parvalbumin and GAD67 immunoreactivity specifically in PV interneurons. These effects were reversible and were also observed with the NR2A-selective antagonist, whereas the NR2B-selective antagonist Ro-25-6981 only partially reduced GAD67 immunoreactivity. Coexposure to the calcium channel opener BayK, or the group I metabotropic glutamate receptor agonist DHPG [(RS)-3,5-dihydroxyphenylglycine] attenuated the decrease in GAD67 and parvalbumin induced by the NMDA receptor antagonists. These results suggest that the activity of NR2A-containing NMDA receptors play a pivotal role in the maintenance of the GABAergic function of PV interneurons.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.4722-05.2006

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 71 · Cited by 329

Authors
Kinney, J. W., Davis, C. N., Tabarean, I., Conti, B., Bartfai, T., & Behrens, M. M.
Affiliations
Scripps Research Institute (US)
Venue
The Journal of Neuroscience
Published
2006-02-01
Volume
26
Issue
5
Pages
1604-1615
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2013209042
Cited by
329
References
71
Citations by year
2026: 4 · 2025: 8 · 2024: 8 · 2023: 12 · 2022: 6 · 2021: 19 · 2020: 14 · 2019: 12 · 2018: 20 · 2017: 14 · 2016: 14 · 2015: 15 · 2014: 21 · 2013: 25 · 2012: 25
FWCI
5.95
Type
journal article
Language
en
Open access
Locations
  • Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Alliance for Research on Schizophrenia and Depression
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
Keywords
NMDA receptor, NR2A subunit, parvalbumin interneurons, GAD67, GABAergic interneurons, ketamine, NVP-AAM077, Ro 25-6981, ERK1/2, CREB phosphorylation, metabotropic glutamate receptors, DHPG, Bay K 8644, schizophrenia, cortical interneurons, glutamatergic signaling
MeSH terms
Animals, Calcium, Cells, Cultured, Glutamate Decarboxylase, Immunohistochemistry, Interneurons, Isoenzymes, Ketamine, Parvalbumins, Phosphorylation, Receptors, N-Methyl-D-Aspartate, N-Methylaspartate, Prosencephalon, Cyclic AMP Response Element-Binding Protein, Patch-Clamp Techniques, Excitatory Amino Acid Antagonists, Extracellular Signal-Regulated MAP Kinases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review